Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial.
Tuber Lung Dis
; 77(3): 239-43, 1996 Jun.
Article
en En
| MEDLINE
| ID: mdl-8758107
SETTING: A medical facility for approximately 90,000 gold miners employed on 24 South African gold mines. OBJECTIVE: To evaluate the effectiveness of rifampicin, isoniazid and pyrazinamide given for 3 months for the prevention of tuberculosis in men with silicosis. DESIGN: A randomised double-blind placebo controlled trial with active 4-year follow up of subjects by routine radiographic screening. RESULTS: A total of 382 gold miners with silicosis were randomised to receive rifampicin 600 mg, isoniazid 400 mg and pyrazinamide 1.25 g daily as Rifater or a placebo. These men have been followed for 4 years since the end of the treatment period. Eleven men who received the combination tablet and 15 men who received the placebo tablet have developed tuberculosis (chi 2 df1 = 0.66, P = 0.4). CONCLUSION: This multi-drug short course chemoprophylaxis regimen has failed to prevent tuberculosis in miners with silicosis. Even if a larger study had demonstrated a statistically significant effect of the regimen as compared with placebo, the rate of tuberculosis in the men who received the three-drug regimen was unacceptably high.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Silicotuberculosis
/
Oro
/
Minería
/
Antituberculosos
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Tuber Lung Dis
Año:
1996
Tipo del documento:
Article
País de afiliación:
Canadá
Pais de publicación:
Reino Unido